Long-acting injectable risperidone

Abstract

Objective: To review the pharmacology, pharmacokinetics, clinical efficacy, and safety profile of long-acting (LA) risperidone for the treatment of schizophrenia.

Data sources: Information was selected from PubMed (1965-July 2004). Applicable scientific posters were also used.

Study selection and data extraction: All published information on risperidone LA was considered. Material providing a comprehensive description was considered.

Data synthesis: Risperidone LA is the first long-acting, injectable atypical antipsychotic. It is dosed at 25-50 mg every 2 weeks. Adverse effects are similar to those seen with oral risperidone. A short-term study showed that risperidone LA is better than placebo in reducing the signs and symptoms of schizophrenia, and a long-term trial showed that stable schizophrenic patients can be switched from either oral or other injectable antipsychotic medications to risperidone LA.

Conclusions: Risperidone LA is efficacious and safe in the treatment of schizophrenia.